182 related articles for article (PubMed ID: 34267347)
1. The novel STAT3 inhibitor WZ-2-033 causes regression of human triple-negative breast cancer and gastric cancer xenografts.
Zhong Y; Deng L; Shi S; Huang QY; Ou-Yang SM; Mo JS; Zhu K; Qu XM; Liu PQ; Wang YX; Zhang XL
Acta Pharmacol Sin; 2022 Apr; 43(4):1013-1023. PubMed ID: 34267347
[TBL] [Abstract][Full Text] [Related]
2. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction.
Park SK; Byun WS; Lee S; Han YT; Jeong YS; Jang K; Chung SJ; Lee J; Suh YG; Lee SK
Biochem Pharmacol; 2020 Aug; 178():114053. PubMed ID: 32450253
[TBL] [Abstract][Full Text] [Related]
3. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM
J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456
[TBL] [Abstract][Full Text] [Related]
4. A chalcone-syringaldehyde hybrid inhibits triple-negative breast cancer cell proliferation and migration by inhibiting CKAP2-mediated FAK and STAT3 phosphorylation.
Jin XX; Mei YN; Shen Z; Zhu JF; Xing SH; Yang HM; Liang G; Zheng XH
Phytomedicine; 2022 Jul; 101():154087. PubMed ID: 35429924
[TBL] [Abstract][Full Text] [Related]
5. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes.
Zhang X; Yue P; Fletcher S; Zhao W; Gunning PT; Turkson J
Biochem Pharmacol; 2010 May; 79(10):1398-409. PubMed ID: 20067773
[TBL] [Abstract][Full Text] [Related]
6. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
[TBL] [Abstract][Full Text] [Related]
7. VGLL4 interacts with STAT3 to function as a tumor suppressor in triple-negative breast cancer.
Song H; Luo Q; Deng X; Ji C; Li D; Munankarmy A; Jian W; Zhao J; Fang L
Exp Mol Med; 2019 Nov; 51(11):1-13. PubMed ID: 31748508
[TBL] [Abstract][Full Text] [Related]
8. GGNBP2 suppresses triple-negative breast cancer aggressiveness through inhibition of IL-6/STAT3 signaling activation.
Liu J; Liu L; Yagüe E; Yang Q; Pan T; Zhao H; Hu Y; Zhang J
Breast Cancer Res Treat; 2019 Feb; 174(1):65-78. PubMed ID: 30450530
[TBL] [Abstract][Full Text] [Related]
9. Eucannabinolide, a novel sesquiterpene lactone, suppresses the growth, metastasis and BCSCS-like traits of TNBC via inactivation of STAT3.
Zhu Z; Yuan J; Xu X; Wei Y; Yang B; Zhao H
Neoplasia; 2021 Jan; 23(1):36-48. PubMed ID: 33217668
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylated STAT3 (Tyr705) as a biomarker of response to pimozide treatment in triple-negative breast cancer.
Dees S; Pontiggia L; Jasmin JF; Mercier I
Cancer Biol Ther; 2020 Jun; 21(6):506-521. PubMed ID: 32164483
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of naphthalene derivatives as potent STAT3 inhibitors and agents against triple-negative breast cancer growth and metastasis.
Yang Z; Xu H; Yang Y; Duan C; Zhang P; Wang Y; Fu K; Shen Y; Xu MX
Breast Cancer Res Treat; 2023 Jan; 197(2):255-267. PubMed ID: 36369502
[TBL] [Abstract][Full Text] [Related]
12. PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer.
Yu TJ; Liu YY; Li XG; Lian B; Lu XX; Jin X; Shao ZM; Hu X; Di GH; Jiang YZ
Cancer Res; 2021 Nov; 81(21):5491-5505. PubMed ID: 34408002
[TBL] [Abstract][Full Text] [Related]
13. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
[TBL] [Abstract][Full Text] [Related]
14. TMEM25 inhibits monomeric EGFR-mediated STAT3 activation in basal state to suppress triple-negative breast cancer progression.
Bi J; Wu Z; Zhang X; Zeng T; Dai W; Qiu N; Xu M; Qiao Y; Ke L; Zhao J; Cao X; Lin Q; Chen XL; Xie L; Ouyang Z; Guo J; Zheng L; Ma C; Guo S; Chen K; Mo W; Fu G; Zhao TJ; Wang HR
Nat Commun; 2023 Apr; 14(1):2342. PubMed ID: 37095176
[TBL] [Abstract][Full Text] [Related]
15. STAT3-induced NCK1 elevation promotes migration of triple-negative breast cancer cells via regulating ERK1/2 signaling.
He P; Sheng J; Qi J; Bai X; Li J; Wang F; Yuan Y; Zheng X
Mol Biol Rep; 2022 Jan; 49(1):267-278. PubMed ID: 34846647
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of MYC and SLC39A10 by a novel natural product STAT3 inhibitor derived from Chaetomium globosum suppresses tumor growth and metastasis in gastric cancer.
Guan X; Yang J; Wang W; Zhao B; Hu S; Yu D; Yuan L; Shi Y; Xu J; Dong J; Wang J; Cheng XD; Qin JJ
Pharmacol Res; 2023 Mar; 189():106703. PubMed ID: 36804016
[TBL] [Abstract][Full Text] [Related]
17. Novel Galiellalactone Analogues Can Target STAT3 Phosphorylation and Cause Apoptosis in Triple-Negative Breast Cancer.
Ko H; Lee JH; Kim HS; Kim T; Han YT; Suh YG; Chun J; Kim YS; Ahn KS
Biomolecules; 2019 May; 9(5):. PubMed ID: 31058868
[TBL] [Abstract][Full Text] [Related]
18. STAT3-induced HLA-F-AS1 promotes cell proliferation and stemness characteristics in triple negative breast cancer cells by upregulating TRABD.
Wu D; Jia H; Zhang Z; Li S
Bioorg Chem; 2021 Apr; 109():104722. PubMed ID: 33618253
[TBL] [Abstract][Full Text] [Related]
19. RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC.
Kim SJ; Ju JS; Kang MH; Eun JW; Kim YH; Raninga PV; Khanna KK; Győrffy B; Pack CG; Han HD; Lee HJ; Gong G; Shin Y; Mills GB; Eyun SI; Park YY
Theranostics; 2020; 10(18):7974-7992. PubMed ID: 32724453
[TBL] [Abstract][Full Text] [Related]
20. Novel potent azetidine-based compounds irreversibly inhibit Stat3 activation and induce antitumor response against human breast tumor growth in vivo.
Yue P; Zhu Y; Brotherton-Pleiss C; Fu W; Verma N; Chen J; Nakamura K; Chen W; Chen Y; Alonso-Valenteen F; Mikhael S; Medina-Kauwe L; Kershaw KM; Celeridad M; Pan S; Limpert AS; Sheffler DJ; Cosford NDP; Shiao SL; Tius MA; Lopez-Tapia F; Turkson J
Cancer Lett; 2022 May; 534():215613. PubMed ID: 35276290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
